Log in

NASDAQ:MIRMMirum Pharmaceuticals Stock Price, Forecast & News

+1.77 (+7.53 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $25.28
50-Day Range
MA: $20.35
52-Week Range
Now: $25.28
Volume216,157 shs
Average Volume55,509 shs
Market Capitalization$641.86 million
P/E RatioN/A
Dividend YieldN/A
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MIRM



Sales & Book Value

Annual SalesN/A
Book Value$5.67 per share


Net Income$-52,550,000.00


Market Cap$641.86 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
+1.77 (+7.53 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MIRM News and Ratings via Email

Sign-up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Mirum Pharmaceuticals (NASDAQ:MIRM) Frequently Asked Questions

How has Mirum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Mirum Pharmaceuticals' stock was trading at $11.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MIRM shares have increased by 115.5% and is now trading at $25.28.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Mirum Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mirum Pharmaceuticals

When is Mirum Pharmaceuticals' next earnings date?

Mirum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Mirum Pharmaceuticals

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals (NASDAQ:MIRM) announced its earnings results on Thursday, August, 6th. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by $0.06.
View Mirum Pharmaceuticals' earnings history

What price target have analysts set for MIRM?

8 equities research analysts have issued twelve-month target prices for Mirum Pharmaceuticals' shares. Their forecasts range from $18.00 to $52.00. On average, they anticipate Mirum Pharmaceuticals' stock price to reach $33.71 in the next twelve months. This suggests a possible upside of 33.4% from the stock's current price.
View analysts' price targets for Mirum Pharmaceuticals

Has Mirum Pharmaceuticals been receiving favorable news coverage?

Media coverage about MIRM stock has trended very negative on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mirum Pharmaceuticals earned a daily sentiment score of -3.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Mirum Pharmaceuticals

Who are some of Mirum Pharmaceuticals' key competitors?

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Gilead Sciences (GILD), Opko Health (OPK), Occidental Petroleum (OXY), Pfizer (PFE), Adaptimmune Therapeutics (ADAP), British American Tobacco (BTI), Crispr Therapeutics (CRSP), Exelixis (EXEL), Fate Therapeutics (FATE) and General Motors (GM).

Who are Mirum Pharmaceuticals' key executives?

Mirum Pharmaceuticals' management team includes the following people:
  • Mr. Michael G. Grey, Exec. Chairman (Age 66)
  • Mr. Christopher Peetz, Pres, CEO & Director (Age 40)
  • Dr. Ian Clements, Sr. VP of Fin. & Communications (Age 50)
  • Dr. Pamela Vig Ph.D., Chief Scientific Officer (Age 48)
  • Ms. Lara Longpre MSC, MBA, Chief Devel. Officer (Age 49)

When did Mirum Pharmaceuticals IPO?

(MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

What is Mirum Pharmaceuticals' stock symbol?

Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM."

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtus ETF Advisers LLC (0.08%), Trexquant Investment LP (0.07%), Chartwell Investment Partners LLC (0.07%), UBS Group AG (0.06%) and New York State Common Retirement Fund (0.01%). Company insiders that own Mirum Pharmaceuticals stock include Christopher Peetz, Edwin Jonathan Tucker, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig and Patrick J Heron.
View institutional ownership trends for Mirum Pharmaceuticals

Which institutional investors are selling Mirum Pharmaceuticals stock?

MIRM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Mirum Pharmaceuticals

Which institutional investors are buying Mirum Pharmaceuticals stock?

MIRM stock was bought by a variety of institutional investors in the last quarter, including Virtus ETF Advisers LLC, Trexquant Investment LP, Chartwell Investment Partners LLC, and New York State Common Retirement Fund. Company insiders that have bought Mirum Pharmaceuticals stock in the last two years include Christopher Peetz, Edwin Jonathan Tucker, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig, and Patrick J Heron.
View insider buying and selling activity for Mirum Pharmaceuticals

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mirum Pharmaceuticals' stock price today?

One share of MIRM stock can currently be purchased for approximately $25.28.

How big of a company is Mirum Pharmaceuticals?

Mirum Pharmaceuticals has a market capitalization of $641.86 million. The company earns $-52,550,000.00 in net income (profit) each year or ($4.58) on an earnings per share basis. Mirum Pharmaceuticals employs 20 workers across the globe.

What is Mirum Pharmaceuticals' official website?

The official website for Mirum Pharmaceuticals is mirumpharma.com.

How can I contact Mirum Pharmaceuticals?

Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The company can be reached via phone at 650-667-4085 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.